Po-05-068 major vascular complications in a large cohort of patients undergoing catheter ablation for vpb/vt in a high-volume, tertiary ep center

Catheter ablation is an established treatment method both in patients with idiopathic premature ventricular complexes (PVC) or ventricular tachycardia (VT) and in structural heart disease (SHD) VT. Major vascular complications (MVCs) are the most frequent in these populations. A retrospective study investigating the incidence of MVCs in large-volume, specialized VT center and analyzing their predictors. We included PVC/VT patients who had their first ablation procedure between August 2006 - December 2020. The procedures were performed under conscious sedation except for patients who were on mechanical ventilation because of hemodynamical or electrical instabilit. Activation mapping supported by an electroanatomic mapping system was used in idiopathic cases. In SHD, substrate mapping using an electroanatomic mapping system and pacemapping was employed as a prerequisite for complete substrate modification during spontaneous rhythm or pacing. Activation and entrainment mapping for well-tolerated VTs were rarely used. The goal of ablation was to abolish all inducible VTs. A specific institutional tracking system for complications of invasive procedures was used to collect all periprocedural complications that were subsequently adjudicated. MVCs were defined as those that result in permanent injury or death, require intervention or treatment, prolong hospitalization (>48 hrs) or require new hospitalization. Idiopathic PVC/VT ablation was performed in 656 pts (males: 50%, age: 51 ± 17 years, re-ablations: 15%). SHD VT was ablated in 1637 pts (males: 88%, age: 63 ± 13 years, re-ablations: 30%, ischemic cardiomyopathy: 65%, left ventricular ejection fraction: 34 ± 13%, electrical storm: 24%). In idiopathic PVC/VT, MVCs were observed in 2.4 % (4.0% in males vs. 0.9% in females, P <0.01). In SHD, the rate of MVCs reached 3.5 % (2.8% in males vs. 9.4% in females, P <0.00001). Based on the multivariable regression model, the composite risk score to predict MVCs was proposed that was calculated as a sum of risk points for age (0, 1, 2, and 3 points for <50, 50–59, 60–69, and ≥70 years, respectively), female gender (2 points), and serum creatinine >1.3mg/dL (2 points), range 0–7 (Figure). While in an idiopathic setting, MVCs were more frequent in males, which may reflect a higher proportion of more complex LV ablations and arterial access, there was a significant female predominance in MVCs in SHD. The composite risk score predicts the risk of MVCs independently of VT cause.